Canadian MS clinics see results with natalizumabReal-world outcomes with investigational drug still favourable Safinamide disappoints in preventing dyskinesia in Parkinson's patientsThe new drug safinamide might have some impact in preventing the involuntary movements characteristic of Parkinson's disease. However, it did not perform any better than placebo over a two-year period. Regional riddle emerges from epilepsy drug study New treatment is effective in Canada and U.S., but not in rest of North America; epilepsy classification may have been a factor Train the brain to ward off dementia Course improves memory by recruiting healthy tissue Evidence lacking for Alzheimer’s drug in mild cases Device uses submarine technology to diagnose stroke quickly Prototype is portable, easy to use Sunlight, vitamin D linked to lower MS risk Research from Australia—which has the highest skin cancer rate in the world—suggests sun exposure also can be viewed in a sort of positive light: It may reduce the risk for developing multiple sclerosis. A window into the body Gilenya: new MS drug approved by Health Canada Health Canada approves first disease-modifying oral treatment for multiple sclerosis in Canada. Brain scans reveal secrets of acupuncture’s success Technique blocks pain signals and reduces expectations of pain, MRI shows First Previous 49 50 51 52 53 Next Last
